Design and Synthesis of Prolylcarboxypeptidase (PrCP) Inhibitors To Validate PrCP As A Potential Target for Obesity
Journal of Medicinal Chemistry2010Vol. 53(19), pp. 7251–7263
Citations Over TimeTop 10% of 2010 papers
Changyou Zhou, Margareta Garcia-Calvo, Shirly Pinto, Matthew Lombardo, Zhe Feng, Kate Bender, KellyAnn D. Pryor, Urmi R. Bhatt, Renee M. Chabin, Wayne M. Geissler, Zhu Shen, Xinchun Tong, Zhoupeng Zhang, Kenny K. Wong, Ranabir Sinha Roy, Kevin T. Chapman, Lihu Yang, Yusheng Xiong
Abstract
Prolylcarboxypeptidase (PrCP) is a serine protease that may have a role in metabolism regulation. A class of reversible, potent, and selective PrCP inhibitors was developed starting from a mechanism based design for inhibiting this serine protease. Compound 8o inhibits human and mouse PrCP at IC(50) values of 1 and 2 nM and is not active (IC(50) > 25 μM) against a panel of closely related proteases. It has lower serum binding than its close analogues and is bioavailable in mouse. Subchronic dosing of 8o in PrCP(-/-) and WT mice at 100 mg/kg for 5 days resulted in a 5% reduction in body weight in WT mice and a 1% reduction in PrCP KO mice.
Related Papers
- → Plant serine proteases: biochemical, physiological and molecular features(2005)187 cited
- → Fibrinogenolytic Proteases Isolated from the Snake Venom of Taiwan Habu: Serine Proteases with Kallikrein-like and Angiotensin-Degrading Activities(2001)28 cited
- → Covalent activity-based probes for imaging of serine proteases(2024)1 cited
- → Serine Proteases and Serine Protease Inhibitors(2008)7 cited
- → Altered levels of plasma kallikrein‐7 in prodromal Alzheimer’s disease(2022)